PolyPeptide Group AG Overview
Valuation check: PPGN.SW's ROE is -5.75%, below the sector sector average of 11.75%.
Get informed when a big investor buys or sells
+ Follow-5.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
PolyPeptide Group AG (PPGN.SW) currently reports a ROE of -5.75%. That is below the sector sector average of 11.75%. Use the charts on this page to explore PolyPeptide Group AG's ROE history and peer comparisons.
PolyPeptide Group AG's ROE of -5.75% is lower than the its sector sector average of 11.75%. That is roughly 149.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but PolyPeptide Group AG's current -5.75% should be judged against industry norms (sector average: 11.75%) and against PPGN.SW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -5.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.75%. From there, open related valuation or income-statement pages for PolyPeptide Group AG, and consider following PPGN.SW for alerts when major investors trade the stock.
